Bristol Myers Squibb (CELG-RI) Dividends Paid - Common (2009 - 2026)
Bristol Myers Squibb (CELG-RI) reported Dividends Paid - Common of $1.3 billion for Q1 2026, up 1.99% year-over-year from $1.3 billion in Q1 2025, and up 1.66% quarter-over-quarter from $1.3 billion in Q4 2025.
Bristol Myers Squibb (CELG-RI) Dividends Paid - Common (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has 18 years of Dividends Paid - Common data on file, last reported at $1.3 billion in Q1 2026.
- Dividends Paid - Common for Q1 2026 came in at $1.3 billion, up 1.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.1 billion (up 3.28% YoY), and the FY2025 annual result was $5.0 billion, up 3.74% from the prior year.
- Dividends Paid - Common climbed to $1.3 billion in Q1 2026 per CELG-RI's latest filing, from $1.3 billion in the prior quarter.
- Over five years, Dividends Paid - Common peaked at $1.3 billion in Q1 2026 and troughed at $12.0 million in Q2 2022.
- A 5-year average of $1.1 billion and a median of $1.2 billion in 2024 frame the typical range for Dividends Paid - Common.
- On a YoY basis, Dividends Paid - Common climbed as much as 9875.0% in 2023 and fell as far as 0.93% in 2023.
- A 5-year view of Dividends Paid - Common shows it stood at $1.1 billion in 2022, then rose by 1.31% to $1.2 billion in 2023, then rose by 5.0% to $1.2 billion in 2024, then climbed by 3.61% to $1.3 billion in 2025, then grew by 1.66% to $1.3 billion in 2026.
- Business Quant data shows CELG-RI's Dividends Paid - Common at $1.3 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.3 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dividends Paid - Common (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -866.88 Mn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 1.55 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 3.13 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 3.09 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 2.11 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 1.36 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 1.04 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 2.45 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 1.28 Bn |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn | 1.28 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.28 Bn |
| Mar 31, 2026 | 1.28 Bn |
| Dec 31, 2025 | 1.26 Bn |
| Dec 31, 2025 | 1.26 Bn |
| Sep 30, 2025 | 1.26 Bn |
| Sep 30, 2025 | 1.26 Bn |
| Jun 30, 2025 | 1.26 Bn |
| Jun 30, 2025 | 1.26 Bn |
| Mar 31, 2025 | 1.26 Bn |
| Mar 31, 2025 | 1.26 Bn |
| Dec 31, 2024 | 1.22 Bn |
| Dec 31, 2024 | 1.22 Bn |
| Sep 30, 2024 | 1.22 Bn |
| Sep 30, 2024 | 1.22 Bn |
| Jun 30, 2024 | 1.22 Bn |
| Jun 30, 2024 | 1.22 Bn |
| Mar 31, 2024 | 1.21 Bn |
| Mar 31, 2024 | 1.21 Bn |
| Dec 31, 2023 | 1.16 Bn |
| Dec 31, 2023 | 1.16 Bn |